Natalizumab Modifies Catecholamines Levels Present in Patients with Relapsing- Remitting Multiple Sclerosis-Reference-Cited by-同舟云学术

Natalizumab Modifies Catecholamines Levels Present in Patients with Relapsing- Remitting Multiple Sclerosis

Published:2016-10-07 Issue:31 Volume:22 Page:4876-4880
ISSN:1381-6128
Container-title:Current Pharmaceutical Design
language:en
Short-container-title:CPD

Author:

M. Escribano Begona,Aguilar-Luque Macarena,Bahamonde Carmen,Conde Cristina,Lillo Rafael,Sanchez-Lopez Fernando,I. Giraldo Ana,H. Cruz Antonio,Luque Evelio,Gascon Felix,Aguera Eduardo,Tunez Isaac

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,Pharmacology

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plasma antioxidant potential measured by total radical trapping antioxidant parameter in a cohort of multiple sclerosis patients;Brain and Behavior;2024-01

2. The small molecule Erk1/2 signaling pathway inhibitor PD98059 improves DNA repair in an experimental autoimmune encephalomyelitis SJL/J mouse model of multiple sclerosis;Mutation Research/Genetic Toxicology and Environmental Mutagenesis;2023-07

3. Dopaminergic Receptor Targeting in Multiple Sclerosis: Is There Therapeutic Potential?;International Journal of Molecular Sciences;2021-05-18

4. The MAP kinase inhibitor PD98059 reduces chromosomal instability in the autoimmune encephalomyelitis SJL/J-mouse model of multiple sclerosis;Mutation Research/Genetic Toxicology and Environmental Mutagenesis;2021-01

5. Clinical and Neurochemical Effects of Transcranial Magnetic Stimulation (TMS) in Multiple Sclerosis: A Study Protocol for a Randomized Clinical Trial;Frontiers in Neurology;2020-08-11